Cargando…

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Bushinsky, David A, Chertow, Glenn M, Cheng, Sunfa, Deng, Hongjie, Kopyt, Nelson, Martin, Kevin J, Rastogi, Anjay, Ureña-Torres, Pablo, Vervloet, Marc, Block, Geoffrey A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473800/ https://www.ncbi.nlm.nih.gov/pubmed/31093680 http://dx.doi.org/10.1093/ndt/gfz111

Ejemplares similares

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066
por: Russo, Domenico, et al.
Publicado: (2020)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
por: Karaboyas, Angelo, et al.
Publicado: (2022)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2023)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
por: Bellasi, Antonio, et al.
Publicado: (2019)

Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
por: Dachy, Guillaume, et al.
Publicado: (2021)

Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing
por: Edson, Katheryne Z., et al.
Publicado: (2016)

Erratum to: Performance of Hemodialysis with Novel Medium Cut-Off Dialyzers
por: Kirsch, Alexander H, et al.
Publicado: (2021)

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis
por: Ye, Jianzhen, et al.
Publicado: (2018)

Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019)

Pharmacokinetics, Biotransformation, and Excretion of [(14)C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
por: Subramanian, Raju, et al.
Publicado: (2016)

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2020)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Sparsity-based photoacoustic image reconstruction with a linear array transducer and direct measurement of the forward model (Erratum)
por: Shang, Ruibo, et al.
Publicado: (2019)

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
por: Fukagawa, Masafumi, et al.
Publicado: (2017)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 2012;61:2922–2931
por: Subauste, AR, et al.
Publicado: (2013)

Anti-Müllerian hormone concentrations in women with chronic kidney disease
por: Wiles, Kate, et al.
Publicado: (2020)

Course of Hyperkalemia in Patients on Hemodialysis
por: Spinowitz, Bruce, et al.
Publicado: (2022)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Erratum to: Porcine Prion Protein as a Paradigm of Limited Susceptibility to Prion Strain Propagation
por: Espinosa, Juan Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_opf7sjecnrnkcho0smfavhev28